Authors' reply to the comment “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa” Correspondence
| Authors: | Ghias, M. H.; Johnston, A. D.; Kutner, A. J.; Micheletti, R. G.; Hosgood, H. D.; Cohen, S. R. |
| Title: | Authors' reply to the comment “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa” |
| Keywords: | treatment outcome; unclassified drug; drug efficacy; drug safety; risk benefit analysis; drug megadose; letter; risk factor; risk assessment; dyspnea; heart palpitation; rigor; paracetamol; anaphylaxis; urticaria; diphenhydramine; immunoglobulin e; mast cell; suppurative hidradenitis; histamine release; infliximab; infusion related reaction; human; priority journal; drug antibody; infliximab antibody |
| Journal Title: | Journal of the American Academy of Dermatology |
| Volume: | 84 |
| Issue: | 4 |
| ISSN: | 0190-9622 |
| Publisher: | Mosby Elsevier |
| Date Published: | 2021-04-01 |
| Start Page: | e203 |
| End Page: | e204 |
| Language: | English |
| DOI: | 10.1016/j.jaad.2020.11.041 |
| PUBMED: | 33253838 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 1 April 2021 -- Source: Scopus |
